DIA Deliverables – Dispatches from the Drug Industry Association 2015 Annual Meeting

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. Once in a blue moon, as the saying goes, the Drug Industry Association and Biotechnology Industry Organization convene their annual conclaves during the same week.  So I spent the […]

Can compliance help marketing and business development?

Journal of Commercial Biotechnology
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Can compliance help marketing and business development?

Go to paper

ABSTRACT: In many FDA-regulated companies, the marketing and business development departments have a quietly antagonistic relationship with their quality and regulatory affairs colleagues. While compliance is supposed to ensure that a safe, efficacious and high-quality new product reaches the marketplace, marketing and business development executives are left to grumble: how are consumers – much less partners and investors – supposed to learn about and get excited about a new product if their work is so constricted? This paper suggests that there is a way to turn compliance from the millstone around Marketing’s neck to the whetstone that helps hone a sharper competitive edge…

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

Get Your WorldView On: 2015 Scientific American Biotech Scorecard #BIO2015

On Thursday June 18th from 12:30 to 2pm in Room 119B Mike May and I will be going over the seventh edition of Scientific American Worldview. Mike is the editor of Worldview. This is a more intimate session than the Super Session (below), and we will discuss the impetus for developing Worldview as well highlighting […]

Drug Patent Expirations for Jun 18, 2015

DrugPatentWatch provides competitive intelligence on small-molecule drugs and the 90,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. FACTIVE (gemifloxacin mesylate) Lg Life Sciences Patent number: 5,962,468 Expiration Date: Jun 15, 2015 TROVAN (trovafloxacin mesylate) Pfizer Patent number: 5,763,454 Expiration Date: Jun 15, 2015 TROVAN PRESERVATIVE […]

Come to my book signing at #BIO2015

I will be signing my textbook Building Biotechnology, and other books, in the BIO bookstore on Thursday June 18th from 10:00 am – 11:30 am. Building Biotechnology is used by dozens of schools, and I am always happy to meet professors, students, and industry professionals who have used the book. Stop by, even if it is just to […]

Latest Licensable Biotechnology Inventions

TechTransferWatch is a search engine and alert service for licenseable technologies from academic labs, foundations, and government. Click the patents below for more details, or visit TechTransferWatch.com for more options. Optogenetic probes for measuring membrane potential Adam E. Cohen, Joel M. Kralj, Adam D. Douglass Harvard Patent number: 9,057,734 Issue Date: June 16, 2015 Molecular […]

Kickstarting biotechnology crowdfunding #BIO2015

A quick note from BIO2015. Biotechnology crowdfunding levels pale in comparison to other industries. There are many reasons for this disparity — risk, high capital requirements, and the technical nature of many biotechnology applications. A talk by Wharton”s Steve Sammut, based on research by Roger Younan, revealed that biotechnology applications are absent from the list […]

Yali Friedman named one of the 100 most influential people in biotechnology by Scientific American #BIO2015

Scientific American has released its list of the 100 most influential people in biotechnology. I am honored to be included in this exclusive list and recognized for my thought leadership on the business of biotechnology. For more than a decade I have had the privilege to be an entrepreneur and academic without borders, researching and developing publications in areas […]

Discussing Biotechnology in Emerging Markets at #BIO2015

Join me and an esteemed set of panelists at the opening plenary for the Emerging Opportunities in Global Markets track at BIO2015. I will be participating in a discussion that delves deeply into the policies and factors that foster (or hinder) biotech industry success in markets around the world, where I will be discussing the Scientific American Worldview project. […]